VIP vs Nonapeptide-1
Side-by-side comparison of key properties, dosing, and research.
Immune SupportSleep Optimization
VIPSkin & Cosmetic
Nonapeptide-1- Summary
- VIP is a 28-amino acid neuropeptide with profound anti-inflammatory, vasodilatory, and immunomodulatory effects. It plays a critical role in gut motility, circadian rhythm, and immune tolerance. Used therapeutically for CIRS (Chronic Inflammatory Response Syndrome), MCAS, and inflammatory conditions.
- Nonapeptide-1 is a synthetic 9-amino acid peptide that inhibits melanin production by blocking α-MSH (alpha-melanocyte stimulating hormone) receptor binding. Used in cosmetic formulations for skin lightening and evening skin tone, it is particularly effective for UV-induced and hormonal hyperpigmentation.
- Half-Life
- ~2 minutes in plasma (rapidly degraded by peptidases); intranasal delivery may extend local CNS effects
- Not applicable (topical)
- Admin Route
- Intranasal, SubQ, IV
- Topical
- Research
- —
- —
- Typical Dose
- 50 mcg (4 sprays of 12.5 mcg each)
- 0.05–0.5% concentration in formulation
- Frequency
- 4x daily
- Twice daily
- Key Benefits
- Potent anti-inflammatory for CIRS and mold illness
- Improves pulmonary hypertension symptoms
- Regulates gut motility and IBS symptoms
- Modulates circadian rhythm and sleep quality
- Reduces mast cell activation (MCAS)
- Improves cognitive function in neuroinflammatory conditions
- Vasodilatory — reduces vascular resistance
- Inhibits UV-induced tanning and hyperpigmentation
- Reduces hormonal melasma
- Evens skin tone at receptor level
- Well-tolerated with minimal irritation
- Complementary to tyrosinase inhibitors for enhanced brightening
- Reduces post-inflammatory hyperpigmentation
- Side Effects
- Facial flushing (transient, intranasal)
- Mild nausea
- Headache at initiation
- Hypotension at high doses
- +1 more
- Generally very well-tolerated
- Rare contact sensitivity in susceptible individuals
- Theoretical risk of excessive depigmentation with prolonged high-concentration use
- Stacks With
- —
- —